Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Amid US ordeal, Moderna wins EU approval for flu/COVID-19 combo shot
Moderna has received European Commission approval for its combination flu and COVID-19 vaccine, mCOMBRIAX, for individuals aged 50 and above across EU member states, Iceland, Liechtenstein, and Norway. This approval marks a significant regulatory win for Moderna, especially given its ongoing challenges and uncertainties regarding the combo shot and its standalone flu vaccine (mRNA-1010) in the U.S. with the FDA. The European approval was granted despite mRNA-1010 not yet being approved as a standalone shot in the EU, a point of surprise for some analysts.